Skip to main content

Malaria, Science, and Social Responsibility

A problem that has seemed intractable for decades may finally be cracking: How to create affordable drug therapies for people who don't offer pharmaceutical companies a commercial market?

Written byBennett Daviss
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00

Courtesy of Peg Skorpinski

A problem that has seemed intractable for decades may finally be cracking: How to create affordable drug therapies for people who don't offer pharmaceutical companies a commercial market?

Jay Keasling, at the University of California, Berkeley; Amyris Biotechnologies, in Emeryville, Calif.; the Institute for OneWorld Health in San Francisco; and the Bill and Melinda Gates Foundation have formed a public-private partnership to produce a genetically engineered version of one of the world's most effective malaria drugs.

Such partnerships aren't new. The International AIDS Vaccine Initiative in New York and the Geneva-based Global Fund to Fight AIDS, Tuberculosis, and Malaria work in a similar way. But the latest collaboration puts a new twist on the idea. A multimillion-dollar grant will be used to pursue an unproven technology that, if it works, will not only be useful against malaria and other ailments, but also will be given to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter
Optimizing SV-AUC for Peptide Therapeutic Analysis

Optimizing SV-AUC for Peptide Therapeutic Analysis

​Beckman Coulter
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen